INTRODUCTION
During the early to mid-2000s, the evaluation of chest pain entered a new era with the emergence and rapid growth in use of multidetector coronary computed tomography (MDCT) angiography [1] . Diagnostic accuracy studies using modern scanners (!64 MDCT) established a high negative predictive value to rule out coronary stenosis as a cause of ischemic chest pain [2] . Cohort studies further established the prognostic value of normal (no coronary plaque or stenosis) or nonobstructive (<50% diameter stenosis) coronary artery disease (CAD) vs. obstructive CAD, and a meta-analysis published in 2011 pooled data from several of these coronary computed tomography angiography (CTA) cohort studies to show the low likelihood of myocardial infarction (MI) or mortality after normal CTA [3] . Furthermore, about one-third of patients were shown to have nonobstructive CAD, which is associated with a small, but significant, increase in absolute event incidence. Finally, patients with obstructive CAD by CTA were shown to have high annualized event rates. Although data continued to accumulate in recent years regarding the diagnostic and prognostic value of CTA, advances in scanner technology and image reconstruction have led to marked reductions in estimated effective radiation dose delivered to the patient, such that CTA scans can now be consistently performed at less than 1 mSv [4] , a fraction of the radiation exposure from CTA just 10 years ago. Other advances in CTA have included the identification of various plaque features that are associated with an increased risk of adverse cardiac events [5] , as well as plaque features that may be associated with ischemia [6] .
Despite these advances and the capabilities of CTA for accurately ruling out coronary stenosis, the specificity of stenosis by CTA for detecting ischemia has been limited. For example, in the Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DEFACTO) trial the per-patient specificity of CTA for identifying flowlimiting stenosis was 42% [7] . Accordingly, several clinical and experimental techniques have been evaluated with the goal of reducing the false positive rate of CTA while maintaining a high level of sensitivity. One such approach is the introduction of fractional flow reserve estimation using conventional coronary CTA [so-called computed tomography derived fractional flow reserve (FFR CT )], which will be the subject of this review. 
KEY POINTS
Coronary CT angiography has a high sensitivity but low specificity for evaluation of possible coronary ischemia.
Several methods have been proposed to improve coronary CTA, one of which is the estimation of invasive FFR from a resting CTA, so-called FFR CT .
Accuracy studies demonstrate that FFR CT improves the specificity of CTA to identify flow-limiting stenosis, but with limited precision and need to send data for processing at increased cost.
There are no randomized trials currently, and thus further data are needed regarding the potential outcomes and cost-effectiveness of management strategies involving FFR CT .
Future studies will continue to evaluate advances in the ability to estimate FFR from CT by FFR CT and other technologies. FFR CT fluid dynamics, the so-called Navier-Stokes equations, were first reported in 1822. Subsequently, these equations have been applied to diverse applications in fluid mechanics and engineering ranging from aeronautics to hydraulics. For the purpose of simulating the potential physiologic significance of coronary stenosis, applying fluid dynamics has been studied for decades, first with invasive angiography and later with coronary CTA. However, current methods involve iteratively solving thousands of mathematical equations to simulate hyperemia, the processing time for which has only recently become practical with improvements in computer processor speed and memory.
Research studies evaluating accuracy of computed tomography derived fractional flow reserve vs. invasive fractional flow reserve Three large multicenter accuracy studies have evaluated the incremental diagnostic value of FFR CT vs. CTA alone using invasive FFR as a reference standard (Table 2) . First, the Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve (DISCOVER-FLOW) Computed From Coronary Computed Tomographic Angiograms [11] study reported that the use of FFR CT in highly selected, routinely acquired CTA datasets in 103 patients (159 vessels) improved the per-vessel accuracy from 59% (sensitivity 91%, specificity 40%) for CTA alone to 84% (sensitivity 88%, specificity 82%) with the addition of FFR CT . Important limitations included the large standard deviation (SD) for FFR CT , which was 12%. Thus, the 95% confidence interval (CI) for the FFR CT point estimate of 0.8 might range from 0.57 (severe stenosis) to 1.0 (normal flow) when compared with invasive FFR. Next, the DEFACTO trial noted an improvement in per-patient accuracy from 64% (sensitivity 84% and specificity 42%) for CTA alone to 73% (sensitivity 90% and specificity 54%) with the addition of FFR CT [7] . In this study, 31 of 285 (11%) CTA studies acquired in experienced centers were reported to be nonevaluable. Like the DISCOVER-FLOW, a similarly imprecise CI was noted in this trial as well.
The third available trial, the so-called Analysis of Coronary Blood Flow Using CT Angiography: Next Steps (NXT) [12] , evaluated 310 patients with both CT and FFR CT and achieved the best accuracy and precision of the available prospective studies, with an improvement in diagnostic accuracy from 65% (sensitivity 83% and specificity 60%) for CTA alone to 86% (sensitivity 84% and specificity 86%) with the addition of FFR CT . As in the DEFACTO study, 47 of 357 (13%) acquired CTA datasets in experienced centers participating in the NXT trial were reported to be nonevaluable. Importantly, the SD improved slightly to AE0.074 in this study, such that the 95% CI for an FFR CT of 0.8 would range for invasive FFR from 0.66 to 0.94. Coronary computed tomography angiography demonstrated a moderate amount of noncalcified plaque associated with positive remodeling (arrow), resulting in moderate (50-69%) stenosis. Computed tomography derived fractional flow reserve across the lesion was 0.85, suggesting that it is unlikely to be hemodynamically significant. The patient was treated with medical therapies and 7 years later remains asymptomatic and without any cardiac events.
In summary, three diagnostic accuracy trials (DISCOVER-FLOW, DEFACTO, and NXT) have evaluated the currently modest ability of FFR CT to improve specificity of CTA without significantly sacrificing sensitivity. However, the clinical utility for individual patients demonstrated by the accuracy in these trials is currently limited by imprecision, as demonstrated by wide limits of agreement with invasive FFR on Bland-Altman analysis.
Computed tomography derived fractional flow reserve in comparison with alternative technologies
In addition to the three clinical trials described above, several single-center and smaller-size observational studies have been published, leading to two systematic reviews and meta-analyses now that summarize the accuracy of FFR CT vs. invasive FFR. A recent meta-analysis identified five studies with 706 patients that compared CTA with or without FFR CT with invasive FFR, and noted that the specificity of CTA improved from 43 to 72% with the addition of FFR CT [13] . In the same meta-analysis, CT stress myocardial perfusion imaging also improved the specificity, from 43 to 77%. A more recent systematic review of the accuracy data for various ischemia tests when compared with invasive FFR as a reference test noted that after pooling data from 609 patients from the DISCOVER-FLOW, DEFACTO, and NXT trials, the low specificity of CTA (39%) could be improved to 78% with the addition of FFR CT [14 & ]. Although not direct comparisons, the specificity of FFR CT was numerically similar to single photon emission computed tomography (SPECT) myocardial perfusion imaging (75%) but lower than stress perfusion MRI (85%).
Alternatively, the anatomic assessment from the CTA could be combined with a physiological evaluation, such as exercise treadmill test (ETT), stress echocardiography, stress myocardial perfusion imaging using nuclear imaging, or cardiac MRI. Indeed, for many patients who may have borderline stenosis by CTA, combining the anatomic information with a simple exercise stress test may provide sufficient information to diagnose prognostically important ischemia and guide patient management [15 && ]. Although untested prospectively, registry data [16] of patients who underwent both exercise test and CTA suggests that combining data from CTA and ETT offers improved risk stratification. Furthermore, the value of CTA þ functional testing was also recently demonstrated in the CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART) trial, in which exercise treadmill testing was performed in $85% of patients [15 && ]. Other solutions to improve the specificity of CTA [e.g., intracoronary transluminal attenuation gradient (TAG)] [17] have been limited by low reliability and variable test accuracy when compared with FFR. ]. This study was an observational comparison of the use of FFR CT among patients referred to either invasive coronary angiography (ICA) or noninvasive testing. FFR CT resulted in increased cost but improved subjective quality of life scores among those evaluated by noninvasive testing, in comparison with a 32% reduction in cost but no change in quality of life scores among those with planned noninvasive testing. This was associated with a 61% reduction in ICA for those in the planned invasive arm of the study. However, there was no comparison of CTA alone among such patients, which by high sensitivity would have likely served a similar gatekeeper role. Although this study represents an important step forward to comparative cost-effectiveness research for FFR CT , it was limited by the nonrandomized design and lack of comparison of FFR CT with CTA alone or with CTA þ functional testing [20, 21] .
Ongoing studies and potential novel applications
Interest in FFR CT continues to grow, although with guarded optimism given the current challenges to work flow, small sample size of accuracy data, lack of extensive real-world experience, and absence of any prospective comparative cost-effectiveness study comparing FFR CT with CTA alone or CTA þ ETT. Likely reflecting these limitations, a search of clinicaltrials.gov for 'FFR CT ' demonstrates few publicly registered actively enrolling studies as of 1 August 2016 (Table 3) .
Current studies have applied, and future studies will continue to pursue, the potential of an interesting emerging application of FFR CT , which is so-called virtual stenting. This process involves estimating the benefit of percutaneous coronary intervention (PCI) by modeling the new FFR CT after improvements in epicardial luminal diameter post-PCI. Of course, PCI in practice does not always result in perfect arterial recanalization and may be complicated by incomplete stent apposition, dissection, jailed side-branches, or injury to the downstream microvasculature or even procedural MI from embolized plaque. Thus, although modeled PCI will never completely predict the final result, use of FFR CT has been suggested as a useful strategy to select the most stenotic lesion upon which to intervene or to prioritize stent placement when multiple lesions exist. One such study demonstrated that a pre-PCI FFR CT of 0.70 AE 0.15 improved to a modeled post-PCI FFR CT of 0.88 AE 0.05 in comparison with pre-PCI FFR of 0.70 AE 0.14 that improved to 0.90 AE 0.05 post-PCI [22] . Pre-PCI bias comparing invasive FFR with FFR CT was 0.006 [95% limits of agreement (LOA) À0.27 to 0.28] and post-PCI bias 0.024 (95% LOA À0.08 to 0.13), indicating a small bias although with wide limits of agreement. This and other proof of concept studies have generated interest in the use of FFR CT to further counsel patients about the potential benefits of PCI for stable ischemic heart disease.
In addition, the proprietary FFR CT patented by Heartflow will compete with other computational techniques, such as automated plaque quantification software (Autoplaq, Cedars Sinai Medical Center, Los Angeles, California) undergoing research evaluation at Cedars Sinai, which also has demonstrated potential for estimation of invasive FFR [23 & ]. Another area of growing interest involves the use of 'machine learning' methods that estimate FFR CT by comparing new images with large databases of previously evaluated CTA, with the advantage of estimating an FFR CT for the new study with a high correlation to physics-based computation but at a fraction of the computation time [24 & ]. Also, methods of estimating FFR from ICA have been investigated, although with less appeal than CTA due to being invasive (while using simulation to avoid stress agents, such as adenosine, that are otherwise used for FFR).
Integrating fractional flow reserve and coronary flow reserve into management of coronary artery disease Conceptually, the FFR calculation refers to the ratio of maximal blood flow in a coronary artery distal to a stenosis to the hypothetical maximal blood flow in the same artery in the absence of a stenosis [25] . As such, FFR is an excellent marker of pressure gradients along a coronary artery that, unlike coronary flow reserve (CFR), is not affected by basal levels of blood flow, which can vary across patients and even within patients over time. Although FFR and ischemia measurements are correlated, this correlation is not one to one. This is because myocardial ischemia results from a complex interaction between focal epicardial stenosis, diffuse atherosclerosis, and microcirculatory function and remodeling (including obstruction and rarefaction) ( Table 1 ). In contrast, CFR measurements integrate both epicardial and microcirculatory components, thereby offering a more precise measure of ischemic burden and clinical risk and, thus, provide potentially complementary information to FFR that may allow better identification of revascularization candidates among patients with stable ischemic heart disease (IHD). Indeed, a global CFR of 1.5 or less by PET is associated with a high risk of coronary events, as compared with global CFR over 2.0 carrying relatively lower risk [26] . Preliminary evidence from a relatively small observational study suggests that coronary artery bypass grafting (CABG) but not PCI in patients with global CFR of less than 1.6 may modify this high-risk natural history [27] . Conversely, revascularization had no apparent survival benefit among patients with either normal or mildly reduced CFR [27] . Additional evidence from a single-center study of 157 patients with stable IHD treated medically offers further insights into the complementary nature of FFR and CFR information in management decisions [28] . Patients with reduced FFR (<0.8) but normal CFR (>2.0) had comparable low risk of adverse events (death, MI, and revascularization) to patients with concordant normal FFR (>0.8) and CFR (>2.0). In contrast, a reduced CFR (<2.0) identified higher-risk patients even when FFR was normal. These findings confirm the prognostic value of physiologic flow measurements independent of focal stenosis or its pressure surrogate. Based on these observations, a multicenter, international study is examining the hypothesis that PCI in lesions with CFR more than 2 despite FFR 0.8 or less can be safely deferred and treated with medical therapy alone [Combined Pressure and Flow Measurements to Guide Treatment of Coronary Stenoses (DEFINE-FLOW), NCT 02328820].
CONCLUSION
In summary, FFR CT has the potential to overcome one of the major contemporary limitations of CTA, a low specificity to identify myocardial ischemia. In a pooled analysis, the specificity of CTA of 39% improved to 78% with FFR CT . However, the current clinical use of FFR CT has been limited by challenging workflow (i.e., need to send CTA datasets to the single proprietary vendor), increased cost, and limited outcomes and cost-effectiveness data compared with CTA alone or CTA þ functional testing. In spite of these limitations, there is continued and growing interest in the potential clinical value of FFR CT in addition to three actively enrolling publicly registered studies.
